Weekly HIV Regimen Meets Phase 3 Goal - Summary - MDSpire

Weekly HIV Regimen Meets Phase 3 Goal

  • By

  • Kathryn Wighton

  • June 10, 2026

Share

Objective:

To evaluate the efficacy and safety of a once-weekly oral regimen combining islatravir and lenacapavir in patients with virologically suppressed HIV.

Approach:
    Key Findings:
    • The safety profile of islatravir/lenacapavir was generally comparable to the comparator regimens.
    Interpretation:

    Limitations:
    • Islatravir and lenacapavir remain investigational and are not approved for use.
    Conclusion:

    Gilead and Merck plan to present findings at a scientific congress and file data with regulatory authorities globally.

    Sources:

Original Source(s)

Weekly HIV Regimen Meets Phase 3 Goal

  • by Kathryn Wighton

  • June 10, 2026

Related Content

Case Report: Cervical lymphadenitis resulting from Pseudomonas aeruginosa diagnosed by metagenomic next-generation sequencing

AAE Revises Dental Trauma Guidance

Recommendations outline splinting, replantation timing, imaging, and long-term surveillance strategies for permanent tooth injuries.

Chemsex Knowledge Gap at the Prescription Counter

Only about one-third of pharmacy professionals could cite prescription drugs associated with chemsex contexts.